PFE - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 26, 2026
5.0/10
Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Significant ongoing patent litigation across multiple key products, with potential material adverse effects on results of operations.. Biopharma revenue decreased by 1.94% to $61.2B in 2025. See detailed pass outputs for comprehensive analysis.

Top Concerns

  • !Total revenues declined 2% in 2025, primarily due to a decrease in COVID-19 product revenues, though operational growth excluding these products was 6%.
  • !The company faces significant revenue headwinds from patent expiries projected from 2026-2030, with an expected $1.5 billion impact in 2026.
  • !Significant increases in intangible assets and goodwill post-acquisition, requiring careful monitoring for impairment.
  • !Estimates for Medicare, Medicaid, and performance-based rebates carry a risk of material adjustment due to long settlement times.
  • !Significant ongoing patent litigation across multiple key products, with potential material adverse effects on results of operations.

Top Positives

  • +Operating cash flow decreased 8% in 2025 due to working capital timing and lower net income, but the company maintains a strong liquidity position.
  • +Strategic priorities include maximizing transaction value, advancing R&D, investing in post-2028 growth, and scaling AI across the business.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is confidently optimistic.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate with $5.0 billion in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows revenue reduction from patent expirations and increasing generic/biosimilar competition as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

4.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

EW 10-K Analysis: $534M Charge Year Masks a 60% Margin Machine

Analysis

MMM 10-K Analysis: Why 3M Reports Two Different Companies in One Filing

Analysis

PFE 10-K Analysis: The Dual Depletion Hiding in Pfizer's Balance Sheet